On assessing the presence of evaluation-time bias in progression-free survival in randomized trials

被引:5
|
作者
Kay, Richard [1 ]
Wu, Jane [2 ]
Wittes, Janet [3 ]
机构
[1] RK Stat Ltd, Great Longstone, England
[2] Genta Inc, Berkeley Hts, NJ USA
[3] Stat Collaborat, Washington, DC USA
关键词
progression-free survival; simulation; logrank test;
D O I
10.1002/pst.443
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluation (or assessment)-time bias can arise in oncology trials that study progression-free survival (PFS) when randomized groups have different patterns of timing of assessments. Modelling or computer simulation is sometimes used to explore the extent of such bias; valid results require building such simulations under realistic assumptions concerning the timing of assessments. This paper considers a trial that used a logrank test where computer simulations were based on unrealistic assumptions that severely overestimated the extent of potential bias. The paper shows that seemingly small differences in assumptions can lead to dramatic differences in the apparent operating characteristics of logrank tests. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [1] Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Shitara, Kohei
    Ikeda, Junko
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Muro, Kei
    Matsuo, Keitaro
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1224 - 1231
  • [2] Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
    Kohei Shitara
    Junko Ikeda
    Tomoya Yokota
    Daisuke Takahari
    Takashi Ura
    Kei Muro
    Keitaro Matsuo
    Investigational New Drugs, 2012, 30 : 1224 - 1231
  • [3] The Waning Relationship Between Progression-Free Survival and Overall Survival in Randomized Cancer Therapy Trials
    Markman, Maurie
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (06) : 30 - 32
  • [4] Bias in progression-free survival analysis due to intermittent assessment of progression
    Zeng, Leilei
    Cook, Richard J.
    Wen, Lan
    Boruvka, Audrey
    STATISTICS IN MEDICINE, 2015, 34 (24) : 3181 - 3193
  • [5] Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival
    Yuki Nakagawa
    Takuya Yoshimoto
    Shintaro Nakagawa
    Yasuo Sugitani
    Hideharu Yamamoto
    Takashi Asakawa
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 1258 - 1264
  • [6] Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival
    Nakagawa, Yuki
    Yoshimoto, Takuya
    Nakagawa, Shintaro
    Sugitani, Yasuo
    Yamamoto, Hideharu
    Asakawa, Takashi
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (06) : 1258 - 1264
  • [7] Testing of evaluation bias for progression free survival endpoint in oncology clinical trials
    Sun, Yan
    Wu, Wenting
    Sargent, Daniel
    STATISTICS IN MEDICINE, 2016, 35 (22) : 3923 - 3932
  • [8] Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer
    Liang, Fei
    Zhang, Sheng
    Wang, Qing
    Li, Wenfeng
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 130 : 36 - 43
  • [9] Design of cancer trials based on progression-free survival with intermittent assessment
    Zeng, Leilei
    Cook, Richard J.
    Lee, Ker-Ai
    STATISTICS IN MEDICINE, 2018, 37 (12) : 1947 - 1959
  • [10] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782